Thromboembolism - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 98
Inquire Before Buying

Thromboembolism - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides an overview of the Thromboembolism (Cardiovascular) pipeline landscape.

When a blood clot (thrombus) breaks and travels in the blood, this is called a thromboembolism. Symptoms include warmth, edema, and erythema, and may also include dilated veins (collaterals) on the chest wall or leg. Risk factors include hypertension, diabetes mellitus, cigarette smoking, and high cholesterol levels. Treatment includes anticoagulants, thrombolytic therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Thromboembolism - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Thromboembolism (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Thromboembolism (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Thromboembolism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 3, 1, 5, 1 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Thromboembolism (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Thromboembolism (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Thromboembolism (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Thromboembolism (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Thromboembolism (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Thromboembolism (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Thromboembolism (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Thromboembolism (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Thromboembolism - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Thromboembolism - Overview
Thromboembolism - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Thromboembolism - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Thromboembolism - Companies Involved in Therapeutics Development
Bayer AG
China Biologic Products Inc
Daiichi Sankyo Co Ltd
F. Hoffmann-La Roche Ltd
GC Pharma
Ionis Pharmaceuticals Inc
Johnson & Johnson
Portola Pharmaceuticals Inc
Tetherex Pharmaceuticals Corp
Verseon Corp
Thromboembolism - Drug Profiles
antithrombin III (human) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1213790 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
betrixaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
edoxaban tosylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GCC-2107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IONIS-FXIRx - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JNJ-9375 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lysimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Inhibit PAI-1 for Arterial Thrombosis and Pulmonary Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein for Thromboembolism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SelK-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TAP-ANV - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRX-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-1902 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VE-2851 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Thromboembolism - Dormant Projects
Thromboembolism - Discontinued Products
Thromboembolism - Product Development Milestones
Featured News & Press Releases
Jun 14, 2018: Verseon to Initiate Phase I Study to Evaluate a New Precision Oral Anticoagulant with Reduced Bleeding Risk
Jun 07, 2018: Verseon presents new data on its precision oral anticoagulants at BIO International Convention 2018
May 18, 2018: LIXIANA (edoxaban) Shows Reduced Rate of a Variety of Types of Intracranial Haemorrhage Compared to Warfarin in New Sub-analysis Presented at the European Stroke Organisation Conference 2018
Mar 23, 2018: Portola Pharmaceuticals Receives and Plans to Appeal Negative CHMP Opinion Regarding Marketing Authorization for Betrixaban in the European Union
Feb 20, 2018: Portola Pharmaceuticals Announces Results of CHMP Oral Explanation for Betrixaban
Dec 19, 2017: FDA Approves Prior Approval Supplement for Commercial Launch of Portola Pharma's Novel Oral Anticoagulant Bevyxxa (betrixaban)
Dec 13, 2017: Once-Daily, Oral LIXIANA (edoxaban) Met Primary Endpoint in Investigational Hokusai-VTE CANCER Study
Nov 30, 2017: Portola Pharmaceuticals to Present New Data on Betrixaban at the 59th American Society of Hematology (ASH) Annual Meeting
Nov 21, 2017: Portola Pharmaceuticals Provides Update on Bevyxxa (betrixaban) Commercial Launch
Nov 07, 2017: Portola Pharmaceuticals Announces New APEX Study Sub-Analyses Data on Betrixaban to be Presented at the America Heart Association Scientific Sessions 2017
Nov 01, 2017: Janssen to Present Abstracts on XARELTO at ASH 2017
Oct 30, 2017: Bayer receives FDA approval for Xarelto 10 mg once daily for the extended treatment of venous thromboembolism
Sep 15, 2017: Bayer receives positive CHMP opinion for rivaroxaban 10 mg once daily for the extended prevention of venous thromboembolism
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Thromboembolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Thromboembolism - Pipeline by Bayer AG, H2 2018
Thromboembolism - Pipeline by China Biologic Products Inc, H2 2018
Thromboembolism - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Thromboembolism - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018
Thromboembolism - Pipeline by GC Pharma, H2 2018
Thromboembolism - Pipeline by Ionis Pharmaceuticals Inc, H2 2018
Thromboembolism - Pipeline by Johnson & Johnson, H2 2018
Thromboembolism - Pipeline by Portola Pharmaceuticals Inc, H2 2018
Thromboembolism - Pipeline by Tetherex Pharmaceuticals Corp, H2 2018
Thromboembolism - Pipeline by Verseon Corp, H2 2018
Thromboembolism - Dormant Projects, H2 2018
Thromboembolism - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Thromboembolism, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products by Targets, H2 2018
Number of Products by Stage and Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Angina (Angina Pectoris) - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 71
    Angina (Angina Pectoris) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Angina (Angina Pectoris) - Pipeline Review, H2 2018, provides an overview of the Angina (Angina Pectoris) (Cardiovascular) pipeline landscape. Angina pectoris is a term that describes chest pain caused by myocardial ischemia. It usually occurs on exertion and is relieved by rest. Angina generally is a symptom of cor......
  • Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 196
    Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Arterial Disease Peripheral Vascular Disease - Pipeline Review, H2 2018, provides an overview of the Peripheral Arterial Disease Peripheral Vascular Disease (Cardiovascular) pipeline landscape. Peripheral vascular disease (PVD) refers to diseases of the blood ve......
  • Critical Limb Ischemia - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 142
    Critical Limb Ischemia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Critical Limb Ischemia - Pipeline Review, H2 2018, provides an overview of the Critical Limb Ischemia (Cardiovascular) pipeline landscape. Critical limb ischemia (CLI) is the most severe form of peripheral arterial disease (PAD). It is caused by chronic inflammatory processes associated with atherosclerosis that resul......
  • Atherosclerosis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 244
    Atherosclerosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2018, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape. Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts......
  • Stroke - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 544
    Stroke - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Stroke - Pipeline Review, H2 2018, provides an overview of the Stroke (Cardiovascular) pipeline landscape. Stroke is a condition in which the brain cells suddenly die because of a lack of oxygen. Symptoms occur rapidly and usually last a short time, from a few minutes to a couple of hours. The symptoms of a stroke usually appear sudd......
  • Arterial Thrombosis - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 54
    Arterial Thrombosis - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Arterial Thrombosis - Pipeline Review, H2 2018, provides an overview of the Arterial Thrombosis (Cardiovascular) pipeline landscape. Arterial thrombosis is a blood clot that develops in an artery. Symptoms include lack of pulse, pain or spasms in the muscles, pale skin and coldness. Depending on where the clot forms, art......
  • Global Congestive Heart Failure Drugs Market Size, Status and Forecast 2018-2025
    Published: 06-Sep-2018        Price: US 3900 Onwards        Pages: 109
    This report focuses on the global Congestive Heart Failure Drugs status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Congestive Heart Failure Drugs development in United States, Europe and China. In 2017, the global Congestive Heart Failure Drugs market size was million US$ and it is expected to reach million US$ by the end of 2025, with a CAGR of during 2018-2025. The key players covered in this study......
  • Global Myocardial Infarction Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 30-Aug-2018        Price: US 3480 Onwards        Pages: 130
    Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occur......
  • Global Heart Failure Drugs Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
    Published: 27-Aug-2018        Price: US 3480 Onwards        Pages: 135
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs